-
Mashup Score: 1Early intervention with daratumumab improves survival for patients with high-risk smouldering myeloma - 18 day(s) ago
Nature Reviews Clinical Oncology – Recent results from the phase III AQUILA trial demonstrate the benefit of fixed-duration monotherapy with daratumumab over observation in patients with high-risk…
Source: www.nature.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2
Nature Reviews Clinical Oncology – Adding brentuximab vedotin to lenalidomide and rituximab improves OS in R/R DLBCL
Source: www.nature.comCategories: General Medicine News, Oncologists1Tweet-
New online! Adding brentuximab vedotin to lenalidomide and rituximab improves OS in R/R DLBCL https://t.co/RohIgJp24m
-
-
Mashup Score: 19Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation? - 22 day(s) ago
Nature Reviews Clinical Oncology – Analysis of circulating tumour DNA (ctDNA) is commonly used for molecular profiling in patients with advanced-stage non-small-cell lung cancer (NSCLC). The…
Source: www.nature.comCategories: General Medicine News, Oncologists1Tweet-
New online! Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation? https://t.co/TCjZHmQpzL
-
-
Mashup Score: 33Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach - 26 day(s) ago
Nature Reviews Clinical Oncology – Tumour-infiltrating lymphocytes (TILs) are crucial effectors of the anticancer immune response and are hypothesized to be key determinants the efficacy of…
Source: www.nature.comCategories: General Medicine News, Oncologists1Tweet-
New online! Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach https://t.co/WgsZQuKcq0
-
-
Mashup Score: 12Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions - 1 month(s) ago
Nature Reviews Clinical Oncology – Despite lower levels of most targetable alterations, a strong association with a history of smoking and generally higher levels of PD-L1 expression, patients with…
Source: www.nature.comCategories: General Medicine News, Oncologists1Tweet-
New online! Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions https://t.co/TZtkkTB4Lr
-
-
Mashup Score: 3Women with clinically node negative breast cancer can safely avoid axillary surgery - 1 month(s) ago
Nature Reviews Clinical Oncology – Women with clinically node negative breast cancer can safely avoid axillary surgery
Source: www.nature.comCategories: General Medicine News, Oncologists1Tweet-
New online! Women with clinically node negative breast cancer can safely avoid axillary surgery https://t.co/ItG6BCRYJW
-
-
Mashup Score: 5
Nature Reviews Clinical Oncology – cfDNA screening for fetal aneuploidy facilitates maternal cancer detection
Source: www.nature.comCategories: General Medicine News, Oncologists1Tweet-
New online! cfDNA screening for fetal aneuploidy facilitates maternal cancer detection https://t.co/py31TScA6L
-
-
Mashup Score: 0Adding blinatumomab to chemotherapy reduces recurrence risk in standard-risk paediatric B-ALL - 2 month(s) ago
Nature Reviews Clinical Oncology – Adding blinatumomab to chemotherapy reduces recurrence risk in standard-risk paediatric B-ALL
Source: www.nature.comCategories: General Medicine News, Oncologists1Tweet-
Adding blinatumomab to chemotherapy reduces recurrence risk in standard-risk paediatric B-ALL https://t.co/dkxAXoUXrv
-
-
Mashup Score: 0FDA approves cosibelimab-ipdl - 2 month(s) ago
On December 13, 2024, the FDA approved cosibelimab-ipdl (Unloxcyt, Checkpoint Therapeutics, Inc.).
Source: www.fda.govCategories: General Medicine News, Oncologists1Tweet-
The FDA has approved the anti-PD-L1 antibody cosibelimab-ipdl for patients with advanced-stage cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation, based on data from Study CK-301-101 (ORR ~47%, mDoR 17+ months): https://t.co/NXUl78wEce
-
-
Mashup Score: 2FDA grants accelerated approval to zenocutuzumab-zbco - 2 month(s) ago
On December 4, 2024, the FDA granted accelerated approval to zenocutuzumab-zbco for non-small cell lung cancer and pancreatic adenocarcinoma.
Source: www.fda.govCategories: General Medicine News, Oncologists1Tweet-
The FDA has granted accelerated approval to the HER2xHER3 bispecific antibody zenocutuzumab for previously treated advanced-stage non-small cell lung cancer or pancreatic adenocarcinoma harbouring NRG1 fusions, based on data from the eNRGy trial: https://t.co/UyVXK0yTxu
-
New online! Early intervention with daratumumab improves survival for patients with high-risk smouldering myeloma https://t.co/OTypWP8hwF